Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

NCT ID: NCT01505608

Last Updated: 2024-08-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2014-12-31

Brief Summary

The purpose of this research study is to evaluate a new investigational drug (TPI 287) for early relapsed neuroblastoma. An investigational drug is one that has not yet been approved by the Food and Drug Administration. This investigational drug is called TPI 287. This study will look at the tumor's response to the study drug, TPI 287, in combination with Irinotecan and Temozolomide versus the combination of Irinotecan and Temozolomide alone. This study will also evaluate the safety and tolerability of the study drug, TPI 287.

Conditions

Neuroblastoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A- Temozolomide and Irinotecan

1. Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.

2. Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.

Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover.

Group Type: ACTIVE_COMPARATOR

Temozolomide

Intervention Type: DRUG

Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle

Irinotecan

Intervention Type: DRUG

Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.

Arm B- Temozolomide/Irinotecan + TPI 287

Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287

1. Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.

2. Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.

3. Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.

Group Type: EXPERIMENTAL

TPI 287

Intervention Type: DRUG

Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.

Temozolomide

Intervention Type: DRUG

Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle

Irinotecan

Intervention Type: DRUG

Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.

Interventions

TPI 287

Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.

Intervention Type: DRUG

Temozolomide

Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle

Intervention Type: DRUG

Irinotecan

Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.

Intervention Type: DRUG

Other Intervention Names

temodar

Eligibility Criteria

Inclusion Criteria

• Subjects must have histologically proven Neuroblastoma and confirmation of primary refractory or recurrent disease with histologic confirmation at diagnosis or at the time of recurrence/progression. Subjects must have primary refractory or have early relapse disease (early relapse disease is defined as having received ≤ one or two relapse therapies).
• Subjects must be age >12 months and diagnosed before the age of 21 years
• Measurable disease, including at least one of the following:

Measurable tumor >10 mm by CT or MRI Positive bone marrow biopsy/aspirate Positive MIBG

• Current disease state must be one for which there is currently no known curative therapy
• Lansky Play Score or Karnofsky scale must be more than 30
• Subjects without bone marrow metastases must have an ANC > 750/μl and platelet count >50,000/μl
• Adequate Renal Function Defined As Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or
• A serum creatinine based on age/gender table
• Adequate liver function must be demonstrated, defined as:

Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age SGPT (ALT) < 10 x upper limit of normal (ULN) for age SGOT (AST) < 10x upper limit of normal (ULN) for age

• No other significant organ toxicity defined as >Grade 2 by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE V4.0- http://ctep.cancer.gov/forms/CTCAEv4.pdf)
• A negative urine pregnancy test is required for female participants of child bearing potential (≥13 years of age or after onset of menses)
• Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
• Informed Consent: All subjects and/or legal guardians must sign written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines
• Subjects may have received microtubulin inhibitors during previous therapies.
• Subjects may have received any number of prior biological therapies.

Exclusion Criteria

• Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects), generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas). Subjects may not have received more than 1 cycle of Irinotecan and Temozolomide as previous relapse therapy.
• Subjects who have received any myeloablative therapy within the previous 2 months.
• Subjects receiving any investigational drug concurrently
• Subjects with serious infection or a life-threatening illness (unrelated to tumor) that is > Grade 2 (NCI CTCAE V4.0), or active, serious infections requiring parenteral antibiotic therapy.
• Subjects with any other medical condition, including malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a subject's ability to sign or the legal guardian's ability to sign the informed consent, and subject's ability to cooperate and participate in the study
• Subjects with known hypersensitivity to any of the components of the drugs to be administered on study.
• Subjects who have previously been treated with TPI 287.

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cortice Biosciences, Inc.

INDUSTRY

Sponsor Role: collaborator

Giselle Sholler

OTHER

Sponsor Role: lead

Responsible Party

Giselle Sholler

Vice Study Chair

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Don Eslin, MD

Role: STUDY_CHAIR

Arnold Palmer Hospital for Children

Locations

Phoenix Children's Hospital

Phoenix, Arizona, United States

Rady Children's Hospital

San Diego, California, United States

Connecticut Children's Hospital

Hartford, Connecticut, United States

Arnold Palmer Hospital for Children- MD Anderson

Orlando, Florida, United States

Helen DeVos Children's Hospital

Grand Rapids, Michigan, United States

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, United States

Cardinal Glennon Children's Medical Center

St Louis, Missouri, United States

Levine Children's Hospital

Charlotte, North Carolina, United States

Countries

United States

Related Links

https://beatcc.org/

Beat Childhood Cancer

Other Identifiers

NMTRC 005

Identifier Type: -

Identifier Source: org_study_id